Animal Health R&D Trends


Animal Pharm's in-depth report - Animal Health R&D Trends - gives you the latest developments on the companies and the new technologies driving animal health research - all the information you need to steer your R&D strategy into the 21st century.


Animal Health R&D Trends looks at the extent to which companies are directing their resources towards new and innovative research compared to the developing existing products. You can find out what product areas are attracting the most R&D activity and find out about new R&D technologies and where they can be sourced from. It analyses three areas of research:

You can also access the latest figures for industry R&D spending. These cover R&D spending in the US, R&D spending in Europe and global R&D spending.


Animal health companies profiled: Bayer; Boehringer Ingelheim; Fort Dodge; Hoechst Roussel Vet; Intervet; Merial; Novartis; Pfizer; Schering-Plough Animal Health


Research specialists profiled: Aquila Biopharmaceuticals; Axis Genetics; Biotech Australia; BresaGen; Heska; MetaMorphix; Mycogen; Peptech Animal Health; Peptide Therapeutics Group; Protein Sciences; Virus Research Institute; Veterinary Infectious Disease Organisation


Published: April 1999
Pages: 119
Ref: SR183E
Price: £395/$830/¥95,000

For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]

CONTENTS
LIST OF TABLES
EXECUTIVE SUMMARY
ABBREVIATIONS


CHAPTER 1 THE ANIMAL HEALTH RESEARCH ENVIRONMENT
1.1 The world market for animal health products
1.1.1 World market value
1.1.2 World market structure
1.1.3 Operating conditions in the animal health sector
1.2 Animal health research
1.2.1 The research process
1.2.2 Industry spending on R&D
1.2.2.1 R&D spending in the US
1.2.2.2 R&D spending in Europe
1.2.2.3 Global industry spending on R&D
1.2.3 The fruits of R&D
1.3 Pressures on animal health research
1.3.1 Market conditions
1.3.2 Parent company demands
1.3.3 Rising costs and increased risk
1.3.4 Consumer and political attitudes
1.3.5 Regulatory approaches
1.4 Research and the regulatory environment
1.4.1 The EU's regulatory overhaul
1.4.2 The rising cost of regulatory compliance
1.4.3 The transatlantic research divide
1.4.4 VICH - rebalancing the research equation
1.5 Maximising R&D resources
1.5.1 In-house synergies
1.5.2 Utilising external resources
1.5.3 Adding value to existing portfolios


CHAPTER 2 KEY AREAS OF CURRENT RESEARCH ACTIVITY
2.1 Immunological research
2.1.1 New technologies
2.1.1.1 Marker vaccines
2.1.1.2 DISC-virus technology
2.1.1.3 Subunit vaccines
2.1.1.4 Expression systems
2.1.1.5 Vector vaccines
2.1.1.6 DNA vaccines
2.1.1.7 Synthetic vaccines
2.1.1.8 Edible vaccines
2.1.1.9 Adjuvant technology
2.1.1.10 Vaccine delivery
2.1.2 Key targets of current immunological research
2.1.2.1 Key disease or parasite targets
2.1.2.2 New roles for immunology
2.2 Pharmacological research
2.2.1 New technologies
2.2.1.1 Screening and molecular design
2.2.1.2 Formulation technology
2.2.1.3 Drug delivery techniques
2.2.2 Key targets of current pharmacological research
2.2.2.1 Anthelmintics and endectocides
2.2.2.2 Ectoparasiticides
2.2.2.3 Antimicrobials
2.2.2.4 Companion animal products
2.3 Genetic research
2.3.1 New technologies
2.3.1.1 Genome mapping
2.3.1.2 Transgenics
2.3.1.3 Cloning
2.3.2 Key targets of current genetic research
2.3.2.1 Disease resistance
2.3.2.2 Production traits


CHAPTER 3 FUTURE DIRECTIONS IN ANIMAL HEALTH RESEARCH
3.1 Factors shaping future research efforts
3.1.1 Corporate activity and parent company requirements
3.1.1.1 Parent company strategies
3.1.1.2 Erosion of traditional research synergies
3.1.2 New technologies
3.1.2.1 Immunology
3.1.2.2 Genetic manipulation
3.1.2.3 Drug delivery
3.1.3 The regulatory environment
3.2 Animal health products for the 21st century
3.2.1 Companion animal products
3.2.1.1 Biologicals
3.2.1.2 Pharmaceuticals
3.2.2 Food animal products
3.2.2.1 Anti-infectives
3.2.2.2 Alternatives to antibacterial therapy
3.2.2.3 Antiparasitics
3.2.2.4 Production enhancers
3.2.2.5 Biologicals
3.2.2.6 Delivery systems
3.3 Animal health research for the 21st century
3.3.1 A two-tier market
3.3.2 Niche players
3.3.3 Specialist research partners


CHAPTER 4 RESEARCH PROFILES
4.1 Animal Health Majors
4.1.1 Bayer
4.1.1.1 Current portfolio and recent launches
4.1.1.2 Research activity
4.1.1.3 R&D pipeline
4.1.2 Boehringer Ingelheim
4.1.2.1 Current portfolio and recent launches
4.1.2.2 Research activity
4.1.2.3 R&D pipeline
4.1.3 Fort Dodge
4.1.3.1 Current portfolio and recent launches
4.1.3.2 Research activity
4.1.3.3 R&D pipeline
4.1.4 Hoechst Roussel Vet
4.1.4.1 Current portfolio and recent launches
4.1.4.2 Research activity
4.1.4.3 R&D pipeline
4.1.5 Intervet
4.1.5.1 Current portfolio and recent launches
4.1.5.2 Research activity
4.1.5.3 R&D pipeline
4.1.6 Merial
4.1.6.1 Current portfolio and recent launches
4.1.6.2 Research activity
4.1.6.3 R&D pipeline
4.1.7 Novartis
4.1.7.1 Current portfolio and recent launches
4.1.7.2 Research activity
4.1.7.3 R&D pipeline
4.1.8 Pfizer
4.1.8.1 Current portfolio and recent launches
4.1.8.2 Research activity
4.1.8.3 R&D pipeline
4.1.9 Schering-Plough Animal Health
4.1.9.1 Current portfolio and recent launches
4.1.9.2 Research activity
4.1.9.3 R&D pipeline
4.2 Research specialists
4.2.1 Aquila Biopharmaceuticals
4.2.1.1 Background
4.2.1.2 Technologies
4.2.1.3 Animal health interests
4.2.2 Axis Genetics
4.2.2.1 Background
4.2.2.2 Technologies
4.2.2.3 Animal health interests
4.2.3 Biotech Australia
4.2.3.1 Background
4.2.3.2 Technologies
4.2.3.3 Animal health interests
4.2.4 BresaGen
4.2.4.1 Background
4.2.4.2 Technologies
4.2.4.3 Animal health interests
4.2.5 Heska
4.2.5.1 Background
4.2.5.2 Technologies and research portfolio
4.2.6 MetaMorphix
4.2.6.1 Background
4.2.6.2 Technologies
4.2.6.3 Animal health interests
4.2.7 Mycogen
4.2.7.1 Background
4.2.7.2 Technologies
4.2.7.3 Animal health interests
4.2.8 Peptech Animal Health
4.2.8.1 Background
4.2.8.2 Technologies and products
4.2.9 Peptide Therapeutics Group
4.2.9.1 Background
4.2.9.2 Technologies and products
4.2.9.3 Animal health interests
4.2.10 Protein Sciences
4.2.10.1 Background
4.2.10.2 Technologies
4.2.10.3 Animal health interests
4.2.11 Virus Research Institute
4.2.11.1 Background
4.2.11.2 Technologies
4.2.11.3 Animal health interests
4.2.12 Veterinary Infectious Disease Organisation
4.2.12.1 Background
4.2.12.2 Technologies
4.2.12.3 Animal health interests


APPENDIX R&D ACTIVITY BY COMPANY/ORGANISATION


LIST OF TABLES
Table 1.1 World market value, 1992-1998
Table 1.2 Sales by region, 1998
Table 1.3 R&D spending by leading multinationals, 1997
Table 1.4 US R&D spending by product category, 1997
Table 1.5 US R&D spending, 1994-1997
Table 1.6 US R&D spending by product category, 1994-1997
Table 1.7 Sales performance of new veterinary pharmaceuticals in the 1990s
Table 1.8 Animal health product revenue ranges
Table 1.9 Products authorised under the EU's centralised registration procedure
Table 1.10 Innovative and defensive research spending in the US, 1994-1997
Table 1.11 The impact of regulatory factors on product development in Europe and the US in real terms, 1992-1997
Table 1.12 Shares of US R&D spending on external resources, 1994-1996
Table 2.1 Marker vaccine development projects
Table 2.2 Vector vaccine development projects
Table 4.1 HRV's near-term development pipeline
Table 4.2 Pfizer's near-term animal health product pipeline
Table 4.3 Heska's vaccine research programme
Table 4.4 Protein Sciences' veterinary vaccine development portfolio
Table 4.5 Vaccines under development by VIDO

EXECUTIVE SUMMARY
Veterinary medicine, which less than half a century ago relied on basic classical vaccines and a limited range of chemical treatments, has been transformed over the past 40 years by the industrialisation of both animal production and veterinary drug research. The movement of human pharmaceutical companies into the veterinary drug sector through the 1960s and 1970s and the application of biotechnology to animal health product research over the past two decades have between them supported the development and commercialisation of comprehensive product ranges which currently generate global sales of $18 billion.


Approaching the end of the 20th century, the animal health industry stands at something of a crossroads. Demand for some of its traditional products has slackened in major markets, research costs are soaring as regulatory frameworks continue to be tightened, and consumer and political attitudes to intensive agricultural production have begun to affect the availability of certain key products.


Sustained growth in demand for companion animal treatments has helped to keep the industry afloat through the 1990s, but will not support its long-term future. New technologies with the potential to transform both livestock production and the animal health industry itself are within reach of researchers in the sector. Turning that potential into commercial reality promises to be a tough challenge, however. The risks associated with heavy investment in novel technologies are continuing to rise as data requirements increase and political influences infiltrate previously science-based regulatory systems.


But long-term success in the sector is still linked fundamentally to the ability of individual companies to bring new and improved products to market. Those who remain committed to the industry must be prepared to invest heavily in research and development (R&D), but must direct financial resources more carefully than ever before.


This report examines the current environment in which R&D-based animal health companies are working and the pressures that are shaping activity in the sector. It looks at current levels of research spending by the industry, the recent results of R&D investment and the methods being utilised by companies in order to maximise their limited research resources.


Key areas of current research are addressed in a section devoted to activity in the fields of immunology, pharmacology and genetics. New technologies and products in each of these areas are identified, along with the companies and organisations involved in significant projects.


The future of animal health research is also examined, along with internal and external factors that are likely to shape R&D activity. The report looks at the type of products that will become key targets in the research portfolios of animal health majors and R&D specialists, and also forecasts changes in ownership for the industry as new stakeholders move into the sector.


The research activities and current R&D interests of 21 organisations, including nine multinationals and 12 research specialists, are profiled in detail. For each multinational, the report outlines current product portfolios and recent launches, research investment levels and R&D projects. For research specialists, background information on individual organisations is followed by a description of core technologies and animal health interests. Finally, in a tabulated appendix to the report, brief details on animal health research projects involving more than 100 organisations are presented.


A decade from now, many of the research projects identified in this report will have moved into the commercial market. Many will also be in the hands of different owners, as corporate activity continues to affect stakeholder shares in the animal health market. Some will have been abandoned, however - either on scientific or economic grounds, or because their path to market was blocked by public and political opposition. And despite the massive potential that new technologies currently offer, it is the acceptability of those technologies to consumers and politicians which will be among the most significant factors regulating the future pace of change in the animal health sector. That fact, above all others, must be borne in mind by research managers as they allocate resources to R&D portfolios that they hope will drive sales through the early part of the next century.

© PJB Publications Ltd. 2000
All rights reserved.